Milde T - Search Results

1

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, Antunes AS, Oehme I, Pekrun A, Pfister SM, Kulozik AE, Witt O, Deubzer HE. Milde T, et al. J Neurooncol. 2012 Dec;110(3):335-48. doi: 10.1007/s11060-012-0978-1. Epub 2012 Oct 6. J Neurooncol. 2012. PMID: 23054560

2

Multifocal osteochondroma after repeated irradiation in a boy with Hodgkin disease.

Milde T, Alamo L, Stadelmann C, Schweigerer L, Witt O. Milde T, et al. J Pediatr Hematol Oncol. 2005 Jun;27(6):344-5. doi: 10.1097/01.mph.0000170886.20335.cb. J Pediatr Hematol Oncol. 2005. PMID: 15956892 No abstract available.

3

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.

Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O. Wegener D, et al. Among authors: milde t. Anticancer Drugs. 2008 Oct;19(9):849-57. doi: 10.1097/CAD.0b013e32830efbeb. Anticancer Drugs. 2008. PMID: 18765999

4

HDAC family: What are the cancer relevant targets?

Witt O, Deubzer HE, Milde T, Oehme I. Witt O, et al. Among authors: milde t. Cancer Lett. 2009 May 8;277(1):8-21. doi: 10.1016/j.canlet.2008.08.016. Epub 2008 Sep 27. Cancer Lett. 2009. PMID: 18824292 Review.

5

Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma.

Milde T, Pfister S, Korshunov A, Deubzer HE, Oehme I, Ernst A, Starzinski-Powitz A, Seitz A, Lichter P, von Deimling A, Witt O. Milde T, et al. Genes Chromosomes Cancer. 2009 Mar;48(3):229-38. doi: 10.1002/gcc.20635. Genes Chromosomes Cancer. 2009. PMID: 19025795

6

Targeting histone deacetylases in neuroblastoma.

Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I. Witt O, et al. Among authors: milde t. Curr Pharm Des. 2009;15(4):436-47. doi: 10.2174/138161209787315774. Curr Pharm Des. 2009. PMID: 19199971 Review.

7

Targeting of HDAC8 and investigational inhibitors in neuroblastoma.

Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. Oehme I, et al. Among authors: milde t. Expert Opin Investig Drugs. 2009 Nov;18(11):1605-17. doi: 10.1517/14728220903241658. Expert Opin Investig Drugs. 2009. PMID: 19780707 Review.

8

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.

Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, Deubzer HE, Lodrini M, Taylor MD, von Deimling A, Pfister S, Witt O. Milde T, et al. Clin Cancer Res. 2010 Jun 15;16(12):3240-52. doi: 10.1158/1078-0432.CCR-10-0395. Epub 2010 Apr 22. Clin Cancer Res. 2010. PMID: 20413433

9

Molecular staging of intracranial ependymoma in children and adults.

Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schöttler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S. Korshunov A, et al. Among authors: milde t. J Clin Oncol. 2010 Jul 1;28(19):3182-90. doi: 10.1200/JCO.2009.27.3359. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516456

10

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.

Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM. Pfaff E, et al. Among authors: milde t. J Clin Oncol. 2010 Dec 10;28(35):5188-96. doi: 10.1200/JCO.2010.31.1670. Epub 2010 Nov 8. J Clin Oncol. 2010. PMID: 21060032

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page